Accumulation of APP-CTF induces mitophagy dysfunction in the iNSCs model of Alzheimer's disease

Seung-Eun Lee1, Daekee Kwon2, Nari Shin1

  • 1Adult Stem Cell Research Center and Research Institute for Veterinary Science, College of Veterinary Medicine, Seoul National University, Seoul, 08826, Republic of Korea.

Cell Death Discovery
|January 11, 2022
PubMed

Insights

Amyloid precursor protein fragments (APP-CTFs) accumulate in mitochondria, causing dysfunction and mitophagy failure in Alzheimer's disease (AD) models. This study reveals APP-CTFs as a key factor in AD pathology, linking mitochondrial damage to disease progression.

Area of Science:

  • Neuroscience
  • Cell Biology
  • Genetics

Background:

  • Mitochondrial dysfunction is a known hallmark of familial Alzheimer's disease (fAD).
  • Amyloid precursor protein (APP) processing generates amyloid-beta (Aβ), but the role of other APP fragments in pathology is less understood.
  • Accumulation of damaged mitochondria contributes to Alzheimer's disease (AD) progression.

Purpose of the Study:

  • To investigate the role of amyloid precursor protein-derived C-terminal fragments (APP-CTFs) in mitochondrial dysfunction and mitophagy in Alzheimer's disease.
  • To elucidate the pathological mechanisms involving APP-CTFs in induced neural stem cells (iNSCs) from AD patients and presenilin knockout models.

Main Methods:

  • Utilized induced neural stem cells (iNSCs) derived from Alzheimer's disease (AD) patient fibroblasts.
  • Analyzed APP-CTFs accumulation within mitochondrial domains.
  • Assessed mitophagy failure using markers like LC3-II, p62, and PTEN-induced kinase 1 (PINK1)/Parkin.
  • Validated findings in presenilin knockout iNSCs (PSEN KO-iNSCs) to confirm the role of gamma-secretase activity.

Main Results:

  • Demonstrated that APP-CTFs accumulate within mitochondria, acting as both a cause and consequence of mitochondrial dysfunction.
  • Showed that APP-CTFs accumulation leads to mitophagy failure, evidenced by altered protein levels and impaired mitochondrial-lysosomal fusion.
  • Confirmed the pathological loop of APP-CTFs accumulation and mitophagy impairment in both AD patient-derived iNSCs and PSEN KO-iNSCs.

Conclusions:

  • APP-CTFs accumulation is a significant contributor to mitochondrial dysfunction and mitophagy failure in Alzheimer's disease.
  • The findings highlight a novel pathological mechanism involving APP-CTFs in AD, distinct from solely Aβ toxicity.
  • Targeting APP-CTFs or enhancing mitophagy may offer new therapeutic strategies for Alzheimer's disease.

Related Concept Videos

Autophagy01:27

Autophagy

Autophagy is a self-digesting process by which a cell protects itself from threats both within and outside the cell, ranging from abnormal proteins to invading bacteria. In this process, obsolete components of the cell and invading microbes are degraded by hydrolytic enzymes active in an acidic environment of the lysosomal lumen.
An autophagic pathway consists of a series of signaling events activated in response to diverse stress and physiological conditions such as food deprivation,...
4.8K
Autophagic Cell Death01:18

Autophagic Cell Death

Christian de Duve discovered “autophagy,” a process in which cellular components are engulfed by membrane-bound organelles called autophagosomes. The autophagosomes then fuse with lysosomes to digest the enclosed contents. Autophagy is generally activated in cells to prevent cell death. However, cell death is triggered when the damage is beyond repair.
Autophagy and Apoptosis
Autophagy can activate apoptosis. In normal conditions, the autophagy activating protein Beclin-1 and...
3.6K
Alzheimer's Disease: Overview01:26

Alzheimer's Disease: Overview

Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
721